Biotechnology Industry
Filter News
Found 28,185 articles
-
Several life sciences companies and life science-focused real estate firms have announced expansion plans as 2021 comes to an end.
-
LAG-3 is a priority focus in cancer immunotherapy because its inhibition has the potential to make PD-1 inhibitors work in more patients.
-
Pfizer's preliminary laboratory studies have shown that the third booster dose increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant.
-
Vyera Pharmaceuticals agreed to pay $40 million to settle federal allegations to radically increase the price of toxoplasmosis drug Daraprim and prevent generic competition.
-
Herophilus Expands Scientific Advisory Board With Appointment of Kenneth Kosik, M.D.
12/8/2021
Herophilus today announced that the company is expanding its scientific advisory board with the appointment of Kenneth S. Kosik, M.A., M.D.
-
ZymoChem Completes $4 Million Seed Financing
12/8/2021
ZymoChem, Inc., an early-stage bioproducts company engineering microbial-based processes for manufacturing industrial chemicals and crafting high-performance materials, today announced that it has closed a $4 million Seed financing.
-
Tessera Therapeutics Adds New Executives to its Leadership Team as the Company Continues to Pioneer Gene Writing™ Technology as New Category in Genetic Medicine
12/8/2021
Tessera Therapeutics Adds New Executives to its Leadership Team as the Company Continues to Pioneer Gene Writing ™ Technology as New Category in Genetic Medicine.
-
NeurOp Receives FDA Orphan Drug Designation for NP10679 for Treatment of Subarachnoid Hemorrhage
12/8/2021
NeurOp, Inc., a clinical-stage biotechnology company focused on neurological and psychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s investigational candidate NP10679 for the treatment of subarachnoid hemorrhage (SAH).
-
CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022
12/8/2021
CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), today announced that its CRO in Brazil (Academic Research Organization (ARO) Albert Einstein Israelite Hospital (AEIH)) met with the Brazilian Health Regulatory Agency (ANVISA) and received its agreement to modify the CD16 trial for critically ill COVID-19 patients.
-
Avistone Pharmaceuticals Secures $200 Million Strategic Investment from Vivo Capital, Bain Capital and Primavera Capital
12/8/2021
Avistone Pharmaceuticals today announced it has received a strategic investment of more than $200 million led by Vivo Capital with participation from Bain Capital and Primavera Capital (collectively the “Investor Group”).
-
EpicentRx Publishes Proof-of-Concept Research on AdAPT-001
12/8/2021
EpicentRx, Inc., today announced publication of an original article entitled "Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-beta" in the American Journal of Cancer Research issue 2156-6976.
-
Valneva Signs Advance Purchase Agreement with Bahrain for Inactivated COVID-19 Vaccine VLA2001
12/8/2021
ValnevaSE, a specialty vaccine company, announced the signing of an advance purchase agreement with the Kingdom of Bahrain for the supply of one million doses of the Company’s inactivated COVID-19 vaccine candidate VLA2001.
-
BioInvent has Submitted a CTA for a Phase 1/2a trial of BI-1607, a Novel anti-FcyRIIB Antibody for the Treatment of Patients with Solid Tumors
12/8/2021
BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces it has submitted a Clinical Trial Application for the novel, fully human FcyRIIB-blocking antibody, BI-1607.
-
Treadwell Therapeutics Announces A Presentation at the 2021 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor
12/8/2021
Treadwell Therapeutics, today announced a presentation for the Company's CFI-402257 program, an oral, best-in-class TTK inhibitor, at the 2021 San Antonio Breast Cancer Symposium (SABCS) being held from December 7-10, 2021.
-
Nanoscope Therapeutics' Optogenetic Gene Therapy to be Featured in Presentation at Stanford University's Innovate Retina Summit Dec. 11, 2021
12/8/2021
Nanoscope Therapeutics Inc announced today the company's Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in a presentation by Michael Singer, M.D., a member of Nanoscope's Clinical Advisory Board, at Stanford University's Innovate Retina summit on December 11, 2021.
-
The news comes just three weeks after Merck paused its Phase II IMAGINE-DR trial, which was studying a combination of islatravir with MK-8507.
-
Odyssey Therapeutics completed an oversubscribed $218 million Series A round. The funds will be used to advance multiple programs from its pipeline and its discovery platform.
-
Recursion entered into a billion-dollar “transformational collaboration” with Roche to identify and develop up to 40 new medications for neuroscience and oncology.
-
Despite having 37 new mutations in the viral spike protein, there does not appear to be any deaths associated with Omicron, although it’s spreading rapidly in South Africa.
-
Surrozen's ethos is “CLIMB ON”. This catchy and focus-appropriate acronym stands for Collaborate, Lead, Innovate, Motivate and be Brave, Open and Nurturing.